VTVT Share Price Performance
US$37.97
24.00 (171.80%)
Price US$37.97
Share Pricen/a
Here's Why We're Not Too Worried About vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation
Dec 02
vTv Therapeutics Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
VTVT Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
vTv Therapeutics Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.89
- -95,117.65%
- -138,058.82%
- 0.5%
About VTVT
- Founded
- 2015
- Employees
- 23
- CEO
- WebsiteView website
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. The company was incorporated in 2015 and is headquartered in High Point, North Carolina.
